Utilidad de la prueba de la nitrato reductasa para la detección rápida de resistencia en Mycobacterium tuberculosis

González, Lorena; Pedraza, Ricardo Sánchez; Murcia, Marta

doi:10.7705/biomedica.v34i0.1694

Cited by 2 publications

(1 citation statement)

References 27 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[8,19,20] Likewise, González (Colombia) recognizes the usefulness of NRA and reports a sensitivity of 91% and 92% for detection of resistance to isoniazid and rifampicin, respectively, as well as specifi city of 100% for both drugs, compared to PM. [21] MDR-TB rates detected in this study, both in new (0.8%) and previously treated cases (5.2%), are consistent with earlier LN-RITLM reports of low circulating levels of MDR M. tuberculosis strains in Cuba. [7,8] The fi nding of new cases with rifampicin and isoniazid resistance constitutes a warning and points out the importance of searching for possible infection sources in such cases.…”

Section: Discussionsupporting

confidence: 92%

Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012–2014

2017

MEDICC Review

View full text Add to dashboard Cite

INTRODUCTION Systematic surveillance of antituberculosis drug resistance allows identifi cation of multidrug-resistant and extensively drug-resistant isolates of Mycobacterium tuberculosis. Surveillance studies of antituberculosis drug resistance systematically conducted in Cuba for over 15 years have revealed low circulation of multidrugresistant tuberculosis, under 1% in new cases. OBJECTIVE Characterize antituberculosis drug resistance in isolates of M. tuberculosis recovered from patients with pulmonary tuberculosis in Cuba in 2012-2014. METHODSThe nitrate reductase assay was used to test 997 isolates of M. tuberculosis for sensitivity to isoniazid and rifampicin. Isolates identifi ed as multidrug resistant were tested for sensitivity to isoniazid, rifampicin, streptomycin, ethambutol, ofl oxacin, amikacin, kanamycin and capreomycin by the proportion method, as well as genetic resistance mutations in rpoB, katG, inhA, gyrA, rrs and embB genes, using GenoType MTBDRplus and MTBDRsl commercial kits. RESULTS Some 95.6% of isolates from new cases and 89.6% of isolates from previously treated patients were sensitive to isoniazid and rifampicin. Multidrug resistance was found in 0.8% of new and 5.2% of previously treated patients, a statistically signifi cant difference. One extensively drug-resistant isolate was detected among previously treated cases. All isolates examined with the molecular method had mutations in the rpoB gene, which is associated with resistance to rifampicin; only seven showed mutations in the katG gene and one in the inhA gene associated with isoniazid resistance. In one isolate, we found mutations in both gyrA and rrs genes, which are associated with resistance to fl uoroquinolones and second-line injectable drugs and therefore, extensive resistance.CONCLUSIONS Results corroborate the low frequency of multidrugresistant and extensively resistant M. tuberculosis strains in Cuba and highlight the need for continuous improvement of surveillance of antituberculosis drug resistance in Cuba.

show abstract

Section: Discussionsupporting

confidence: 92%

Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012–2014

2017

MEDICC Review

View full text Add to dashboard Cite

show abstract

Molecular Diagnosis of Tuberculosis

et al. 2018

View full text Add to dashboard Cite

Tuberculosis (TB) is one of the leading causes of adult death in the Asia-Pacific Region, including Indonesia. As an infectious disease caused by Mycobacterium tuberculosis (MTB), TB remains a major public health issue especially in developing nations due to the lack of adequate diagnostic testing facilities. Diagnosis of TB has entered an era of molecular detection that provides faster and more cost-effective methods to diagnose and confirm drug resistance in TB cases, meanwhile, diagnosis by conventional culture systems requires several weeks. New advances in the molecular detection of TB, including the faster and simpler nucleic acid amplification test (NAAT) and whole-genome sequencing (WGS), have resulted in a shorter time for diagnosis and, therefore, faster TB treatments. In this review, we explored the current findings on molecular diagnosis of TB and drug-resistant TB to see how this advancement could be integrated into public health systems in order to control TB.

show abstract

Utilidad de la prueba de la nitrato reductasa para la detección rápida de resistencia en Mycobacterium tuberculosis

Cited by 2 publications

References 27 publications

Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012–2014

Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012–2014

Molecular Diagnosis of Tuberculosis

Contact Info

Product

Resources

About